ClinicalTrials.gg
RecruitingNCT07204977Updated Oct 1, 2026

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

A Phase 1 interventional study of Acamprosate calcium in Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS). Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by National Institute of Neurological Disorders and Stroke (NINDS) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Amyotrophic Lateral Sclerosis by National Institute of Neurological Disorders and Stroke (NINDS) — 2 open to participants now, 2 under way, none of them phase 3. Amyotrophic Lateral Sclerosis · National Institute of Neurological Disorders and Stroke (NINDS).

Started
2026
the only one that year
Phase 1
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Amyotrophic Lateral Sclerosis by National Institute of Neurological Disorders and Stroke (NINDS), this one is the only one that started in 2026, is one of 2 in phase 1, and was the 11th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 11 studies in Amyotrophic Lateral Sclerosis by National Institute of Neurological Disorders and Stroke (NINDS) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyotrophic Lateral Sclerosis by National Institute of Neurological Disorders and Stroke (NINDS), or all of them as a file.
02

Study summary

Background:

Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time. Half of all people with ALS live only 3 to 5 years after diagnosis. Current drug treatments can slow the progress of the disease, but they cannot stop or reverse it.

Objective:

To test a study drug (acamprosate) in people with ALS with a mutation in the C9orf72 gene.

Eligibility:

People aged 18 years and older with ALS. They must have a mutation in the C9orf72 gene.

Design:

Participants will have 13 visits over 32 weeks. Five visits will be at the clinic, and 8 visits will be by phone.

Participants will have a baseline visit of up to 3 days. They will have a physical exam with blood tests. They will have imaging scans and tests of their breathing ability. Their memory, thinking, and behavior will be assessed. They will have a neurologic exam to check their reflexes, strength, balance, eyes, and coordination. They will complete questionnaires about their daily life. They will have a lumbar puncture to collect fluid from the area around the spinal cord.

Acamprosate is a pill taken by mouth. Participants will take 2 pills by mouth 3 times a day with meals for 24 weeks. They will record their doses and any missed doses in a diary.

Baseline tests will be repeated during follow-up clinic visits. These tests may be spread out over 3 days.

During phone visits, participants will talk about how they are doing. They will review their diary with researchers.

Read the detailed description

Study Description:

This study will evaluate the safety and clinical effects of acamprosate in patients diagnosed with amyotrophic lateral sclerosis who have a hexanucleotide repeat expansion in the C9orf72 gene. A drug repurposing evaluation using genomic data from C9orf72 genetic mutation carriers showed that acamprosate may have a neuroprotective effect in this group of patients in silico and experiments. To examine the in vitro effect, iPSC derived motor neurons from ALS patients with C9orf72 repeat expansion were treated with acamprosate and reduced cell death was observed. Exploratory endpoints will include the effect of acamprosate on ALS disease progression.

Objectives:

Primary objective: To assess the safety of acamprosate in patients with ALS and mutation in C9orf72.

Secondary objective: To investigate the clinical effects of acamprosate in patients with ALS and mutation in C9orf72.

Exploratory objective: To investigate the clinical, laboratory, and neuroimaging effects of acamprosate in patients with ALS and mutation in C9orf72.

Endpoints:

Primary endpoint: Adverse events (AEs), Serious Adverse Events (SAEs), and laboratory abnormalities during treatment. Each AE will be categorized according to its severity, its relation to the study intervention, its frequency, and its outcome.

Secondary endpoint: The change in ALS Functional Rating Scale-Revised (ALSFRS-R) score from baseline at predetermined time points during the study.

Exploratory endpoint: The change ALS disease severity and quality of life scales, neurodegeneration biomarkers, and neuroimaging measures from baseline at predetermined time points during the study.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease

Keywords

  • Amyotrophic Lateral Sclerosis
  • Clinical Trial
  • Acamprosate
  • C9ORF72
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following inclusion criteria:

  1. Aged 18 years or older at the time of the screening visit.
  2. Able to provide and comply with study procedures and availability for the duration of the study. If a participant lacks capacity to give consent, a Legally Authorized Representative (LAR) will be authorized to give consent on behalf of the individual.
  3. Diagnosis of ALS (possible, probable, or definite according to the World Federation of Neurology El Escorial revised criteria or the Gold Coast Criteria) with or without mild cognitive impairment, mild behavioral impairment, or frontotemporal dementia (FTD).
  4. CLIA-certified genetic testing showing a pathogenic hexanucleotide repeat expansion in the C9orf72 gene.
  5. Symptom duration less than 2 years, or if greater than 2 years, disease progression at a rate that, in the judgement of the investigator, would allow for completion of the study.
  6. If taking riluzole, edaravone, or phenylbutyrate/TUDCA, the participant must be on a stable dose for at least 30 days prior to the screening visit, or have stopped taking riluzole, edaravone, or phenylbutyrate/TUDCA at least 30 days prior to the baseline visit.
  7. Participant must be competent to self-administer the medication as deemed by study team. Alternatively, participant must have a competent caregiver who can and will be responsible for administering the study drug. If there is no caregiver, another qualified individual must be available to administer the study drug.
  8. Participant has established care with a neurologist and will maintain this clinical care throughout the study.
  9. For females of : use of effective or highly effective for at least one month prior to screening and agreement to use such a method during study participation and for an additional 8 weeks after the end of acamprosate administration. Participants of must have a negative pregnancy test at screening.
  10. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Dependence on daytime mechanical ventilation (invasive or non-invasive, including Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) at the time of the screening visit.
  2. Participation in any other drug trial or using investigational drug(s) (within 4 weeks prior to the Day 0 visit and thereafter).
  3. Participants must not become pregnant or breastfeed for the duration of the study. Participants of must have a negative pregnancy test at screening and be non-lactating.
  4. Men who are trying to become fathers or donate sperm.
  5. History of positive test or positive result at screening for .
  6. History of severe sulfite allergy (i.e., anaphylaxis).
  7. Presence of any of the following clinical conditions at the time of screening:

    1. Active drug abuse or alcoholism.
    2. Unstable medical condition that, in the opinion of the investigators, makes participation unsafe.
    3. Renal impairment estimated \<=60mL/min/1.73m\^2.
    4. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit.
  8. Safety Laboratory Criteria at the screening visit:

    1. Estimated glomerular filtration rate \<=60mL/min/1.73m\^2.
    2. concentration of \<100,000/microl.
    3. PT and >1.2 times the .
    4. \<10mg/dL.
    5. Positive Surface Antigen and Virus Antibody
  9. Participants who are unable to swallow tablets whole, as required by the administration guidelines. This includes individuals with any medical condition or physical limitation that impedes their ability to swallow solid dosage forms.
  10. Participants who are dependent on a gastrostomy tube for medication administration. Since acamprosate is in tablet form that cannot be crushed or altered, it is unsuitable for administration through a gastrostomy tube.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Intervention

    This is a single arm study, capturing the safety profile of acamprosate over the course of the study.

    Drug: Acamprosate calcium

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of acamprosate in patients with ALS and mutation in C9orf72.

    Incidence of adverse events and serious adverse events and abnormalities in laboratory tests (complete blood count, acute care panel, hepatic and mineral panel).

    Time frame: Six months

Secondary outcomes

  1. To investigate the clinical effects of acamprosate in patients with ALS and mutation in C9orf72.

    Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score from baseline at predetermined time points during the study.

    Time frame: Six months.

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

Of 30 non-industry phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's planned 19 months is below that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 3, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 1, 2026
Sites
National Institutes of Health Clinical Center is now Recruiting
Oct 1, 2026
Contact
Study contact now listed: added c•••@nih.gov · •••1229; added j•••@nih.gov · •••7428. See the current contact
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Institutes of Health Clinical Center · Bethesda, United StatesContact added c•••@nih.gov · •••1222
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Active, not recruiting→Recruiting
    National Institutes of Health Clinical Center is now Recruiting
    Contact Study contact now listed: added c•••@nih.gov · •••1229; added j•••@nih.gov · •••7428. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Institutes of Health Clinical Center · Bethesda, United StatesContact added c•••@nih.gov · •••1222
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07204977
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Feb 2, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Carol H Hoffman
Contact
carol.hoffman@nih.gov
(301) 451-1229
Justin Y Kwan, M.D.
Contact
justin.kwan@nih.gov
(301) 496-7428
Justin Y Kwan, M.D.
principal investigator · National Institute of Neurological Disorders and Stroke (NINDS)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acamprosate

Start the discussion